<DOC>
	<DOCNO>NCT00003711</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy pemetrexed disodium irinotecan treating patient metastatic solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose LY231514 follow irinotecan patient metastatic cancer . II . Determine quantitative qualitative toxicity LY231514 combination irinotecan patient . III . Assess plasma pharmacokinetics patient treat regimen . IV . Document antitumor activity regimen patient . OUTLINE : This dose escalation study . Patients receive LY231514 IV 10 minute follow irinotecan IV 90 minute day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos LY231514 irinotecan . If escalation one drug combination result unacceptable dose limit toxicity ( DLT ) , drug escalate . Instead , dose drug decrease safe dose , second drug escalate unacceptable DLT result . If DLT occur 2 6 patient level , dose escalation stop . The maximum tolerate dose defined high dose few 2 6 patient experience DLT course 1 2 . PROJECTED ACCRUAL : Up 42 patient accrue study .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven metastatic solid tumor refractory standard therapy potentially effective therapy exist No leukemia , lymphoma , multiple myeloma Measurable evaluable disease No pleural peritoneal effusion No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin normal AST ALT great 3 time normal ( great 5 time normal liver involvement present ) Albumin least 2.5 g/dL Renal : Creatinine clearance least 45 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception 3 month study No active infection No concurrent serious systemic disorder Body surface area great 3.0 m2 PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 3 week since prior chemotherapy recover No prior LY231514 irinotecan No great 6 prior course regimen contain alkylating agent ( except low dose cisplatin ) No great 4 prior course carboplatincontaining regimen No prior mitomycin No concurrent chemotherapy Endocrine therapy : No concurrent hormone therapy ( except contraceptive corticosteroid ) Radiotherapy : No prior radiotherapy 25 % bone marrow No prior radiotherapy whole pelvis Recovered prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : At least 4 week since prior investigational agent No concurrent experimental medication No aspirin nonsteroidal antiinflammatory agent 2 day prior , day , 2 day dose LY231514 ( 5 day prior LY231514 long act agent piroxicam )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>